phase II clinical study
AstraZeneca, Daiichi Sankyo File for FDA Enhertu Approval in Second-Line HER2-Postive Breast Cancer
The agency has accepted the firms' supplemental biologics application for the antibody-drug conjugate and is expected to make a decision by Q2 2022.
Tempus, GSK Initiate Phase II Trial of Niraparib in PALB2-Mutated Tumors
Tempus will screen patients sequenced through its platform for PALB2 mutations to accelerate trial enrollment.
BridgeBio, Amgen to Study SHP2 Inhibitor, Lumakras Combo in KRAS-Mutant Tumors
The nonexclusive collaboration further extends Amgen's ability to explore combination treatment approaches with sotorasib in a pan-tumor fashion.
Theseus Begins First-in-Human Trial of KIT Inhibitor in Gastrointestinal Stromal Tumor Patients
THE-630 is designed to treat GIST that has stopped responding to therapy through the acquisition of multiple KIT mutations.
FDA Clears Jubilant Therapeutics' IND Allowing for LSD1/HDAC6 Inhibitor Clinical Trial
The company will evaluate JBI-802 in solid tumors, including small cell lung cancer and treatment-induced neuroendocrine prostate cancer.